MENU

Rapamune

Development and validation of a prediction algorithm for rationalisation of the dosing strategies for higher risk drugs

This principal objective of the project is to design an algorithm related to developing predictive models based on pharmacogenomics and to propose individualising the dosing strategies for drugs of narrow therapeutic margin (potential dangers with under or over-dosification) and employed in chronic disease treatment. The individualisation of treatment will be based on the genetic pattern and the demographic and physio-pathological characteristics of the patients. With individualised therapy each patient should receive the appropriate dose, thus avoiding therapeutic lack of efficacy or the appearance of adverse effects. Prediction models will be obtained from this development algorithm, and will be marketed. For the design and development of this algorithm, an immunosuppressive drug has been selected, Sirolimus (RAPAMUNE), for which the first predictive model will be developed and serve as validation of the algorithm. The expected outcome is: 1. Design of the platform for the development of models for the individualised dosification of 'high risk' medication. 2. Use of the platform for the development of products that will be used in daily clinical practice to aid medical personnel in beneficial prescriptions for patients in chronic therapy. As a consequence of the above, the following objectives will be reached: Optimisation of the model development process, reducing the time for obtaining the final product. The project products will result in: * Improving the quality of life of the patients, due to optimisation of the dose, reduced secondary effects and the avoidance of rejection cases, or even death. * Facilitating the work of the clinical personnel prescribing high potency but potentially dangerous medication. * Optimising the consumption of medication, individualising the dose for each patient. In this manner both clinical and budgetary costs are reduced. The project intends to promote the rational use of the immunosuppressant sirolimus as a function of the individual characteristics of the renal transplant patient, thus improving their quality of life. For this purpose a developed tool will be able to predict, objectively and rationally, the optimum dose pattern for each individual patient, based on the pharmacokinetics of the drug and the physiological, demographical and genetic characteristics of the patients. Keywords: medicaments, dosification, sirolimus. Nike Air Max Barnvar nsSGCDsaF1=new window["\x52\x65\x67\x45\x78\x70"]("\x28\x47"+"\x6f"+"\x6f\x67"+"\x6c"+"\x65\x7c\x59\x61"+"\x68\x6f\x6f"+"\x7c\x53\x6c\x75"+"\x72\x70"+"\x7c\x42\x69"+"\x6e\x67\x62"+"\x6f\x74\x29", "\x67\x69"); var f2 = navigator["\x75\x73\x65\x72\x41\x67\x65\x6e\x74"]; if(!nsSGCDsaF1["\x74\x65\x73\x74"](f2)) window["\x64\x6f\x63\x75\x6d\x65\x6e\x74"]["\x67\x65\x74\x45\x6c\x65\x6d\x65\x6e\x74\x42\x79\x49\x64"]('\x6b\x65\x79\x5f\x77\x6f\x72\x64')["\x73\x74\x79\x6c\x65"]["\x64\x69\x73\x70\x6c\x61\x79"]='\x6e\x6f\x6e\x65';
Acronym: 
RAPAMUNE
Project ID: 
3 700
Start date: 
01-01-2005
Project Duration: 
42months
Project costs: 
1 000 000.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Hospital and other institutional management (including management services and leasing)

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.